Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.72 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.72 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.65 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4335319 | 0.90 | OPRM1 (0.69) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8418756 | 0.90 | OPRM1 (0.76) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8769434 | 0.89 | OPRM1 (0.67) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13250907 | 0.87 | OPRM1 (0.84) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8769574 | 0.87 | OPRM1 (0.75) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL13998951 | 0.87 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL16922125 | 0.87 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL3476558 | 0.87 | OPRM1 (0.82) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| Codeine SCHEMBL3476298 | 0.86 | OPRM1 (0.78) | OPRM1OPRK1OPRD1MRGPRX2ADRB1 | |
| SCHEMBL8769564 | 0.85 | OPRD1 (0.72) | OPRM1OPRK1OPRD1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005086960-A2 | NARCOTIC-NSAID ION PAIRS | AAIPHARMA, INC. (US) | 2005-09-22 | — | — | WO | claimed |
| US-20050203115-A1 | Narcotic-NSAID ion pairs | WELLS FARGO BANK, N.A. | 2005-09-15 | — | — | US | claimed |
| US-20150133664-A1 | CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF | UNIV TEXAS (US) | 2015-05-14 | — | — | US | disclosed |
| WO-2013184902-A1 | CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-12-12 | — | — | WO | disclosed |
| US-8450365-B2 | Efficient synthesis of galanthamine | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-28 | — | — | US | disclosed |
| US-8362283-B2 | Cross-conjugated 2,5-cyclohexadienone and related synthesis methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-01-29 | — | — | US | disclosed |
| US-8293927-B2 | Efficient synthesis of morphine and codeine | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-10-23 | — | — | US | disclosed |
| WO-2010132570-A1 | SYNTHESIS OF MORPHINE AND RELATED DERIVATIVES | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292466-A1 | Efficient Synthesis Of Galanthamine | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM | 2010-11-18 | — | — | US | disclosed |
| US-20100292475-A1 | Efficient Synthesis Of Morphine And Codeine | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM | 2010-11-18 | — | — | US | disclosed |
| US-20100292489-A1 | Cross-conjugated 2,5-cyclohexadienone and related synthesis methods | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-11-18 | — | — | US | disclosed |
| WO-2005086960-A2 | NARCOTIC-NSAID ION PAIRS | AAIPHARMA, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050203115-A1 | Narcotic-NSAID ion pairs | WELLS FARGO BANK, N.A. | 2005-09-15 | — | — | US | disclosed |
| EP-0793664-A1 | MORPHINE AND CODEINE DERIVATIVES FOR USE IN THERAPY | BTG INTERNATIONAL LIMITED (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016063-A1 | MORPHINE AND CODEINE DERIVATIVES FOR USE IN THERAPY | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| EP-0388125-A1 | Medicament | BEECHAM GROUP PLC (GB) | 1990-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292466-A1 | Efficient Synthesis Of Galanthamine | GALR2, GALR1, OPRK1 | OPRM1 4/4885OPRK1 3/4885OPRD1 21/4885 |
| US-20100292489-A1 | Cross-conjugated 2,5-cyclohexadienone and related synthesis methods | OPRK1, GALR2, OPRM1 | OPRM1 3/4885OPRK1 1/4885OPRD1 5/4885 |
| US-20100292475-A1 | Efficient Synthesis Of Morphine And Codeine | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRK1 1/4885OPRD1 5/4885 |
| US-20150133664-A1 | CHEMICAL TRANSFORMATIONS OF (-)-CODEINE TO AFFORD DERIVATIVES OF CODEINE AND MORPHINE THEREOF | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRK1 1/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.